Oren Livnat believes MNKD’s revised debt arrangements will be advantageous to the Afrezza launch.
MannKind Corporation (NASDAQ:MNKD) and BIOMM announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza® (insulin human) inhalation powder …
MannKind Corporation (NASDAQ:MNKD) shares inched lower on Wednesday after rising to 52-week highs in the previous session. The reason?
Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.
Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.
Analyst says MannKind’s Afrezza revenues can surpass debt, if investors can be patient for adoption.
Investors are racing to buy MannKind Corporation (NASDAQ:MNKD) shares following the news that the FDA has approved a labeling revision for the company’s diabetes …
Will Mannkind file bankruptcy? Jason Kolbert says no.
James “Jim” Flynn first walked onto the Deerfield Management team seventeen years ago, since a firm that cares about strides in the healthcare …
MannKind Corporation (NASDAQ:MNKD) announced today the company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park …
